[go: up one dir, main page]

MX2018016332A - Quimioterapias de combinacion. - Google Patents

Quimioterapias de combinacion.

Info

Publication number
MX2018016332A
MX2018016332A MX2018016332A MX2018016332A MX2018016332A MX 2018016332 A MX2018016332 A MX 2018016332A MX 2018016332 A MX2018016332 A MX 2018016332A MX 2018016332 A MX2018016332 A MX 2018016332A MX 2018016332 A MX2018016332 A MX 2018016332A
Authority
MX
Mexico
Prior art keywords
treatment
oxygen species
reactive oxygen
hyperproliferative
ros
Prior art date
Application number
MX2018016332A
Other languages
English (en)
Inventor
Mousses Spyro
Original Assignee
Systems Oncology Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Systems Oncology Llc filed Critical Systems Oncology Llc
Publication of MX2018016332A publication Critical patent/MX2018016332A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/131—Amines acyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Combinación de agentes que aumentan la cantidad de especies reactivas de oxigeno con agentes que son activados, mejorados o inducidos por especies reactivas de oxígeno para el tratamiento del cáncer y enfermedad precancerosa. Composiciones farmacéuticas que comprenden un agente terapéutico o un fármaco que genera o produce especies reactivas de oxigeno (ROS) en un miaoambiente de enfermedad. y al menos un fármaco o agente que es activado, mejorado o inducido por ROS para el tratamiento de cáncer de mamíferos. trastornos displásicos. neoplásicos o hiperproliferativos y métodos de uso de los mismos para el tratamiento cáncer de mamíferos, trastornos displásicos. neoplásicos o hiperproliferativos.
MX2018016332A 2016-06-27 2017-06-23 Quimioterapias de combinacion. MX2018016332A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662355293P 2016-06-27 2016-06-27
PCT/US2017/038964 WO2018005279A1 (en) 2016-06-27 2017-06-23 Combination chemotherapies

Publications (1)

Publication Number Publication Date
MX2018016332A true MX2018016332A (es) 2019-11-28

Family

ID=60787634

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018016332A MX2018016332A (es) 2016-06-27 2017-06-23 Quimioterapias de combinacion.

Country Status (13)

Country Link
US (1) US20200179417A1 (es)
EP (1) EP3558317A4 (es)
JP (1) JP2019518795A (es)
KR (1) KR20190025646A (es)
CN (1) CN109689060A (es)
AU (1) AU2017291411A1 (es)
BR (1) BR112018076639A2 (es)
CA (1) CA3029228A1 (es)
EA (1) EA201892834A1 (es)
IL (1) IL263785A (es)
MX (1) MX2018016332A (es)
WO (1) WO2018005279A1 (es)
ZA (1) ZA201808608B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018212159A1 (ja) * 2017-05-15 2018-11-22 浜松ホトニクス株式会社 カテーテルキット
US11717511B2 (en) 2018-04-09 2023-08-08 Huen Co., Ltd. Pharmaceutical composition comprising derivative compound of 1,2-naphthoquinone for preventing or treating solid cancer or blood cancer
EP3777852B1 (en) * 2018-04-09 2025-07-02 Yungjin Pharm. Co., Ltd. Pharmaceutical composition including 1,2-naphthoquinone derivative compound for prevention or treatment of solid cancers or blood cancers
WO2020246807A2 (ko) * 2019-06-04 2020-12-10 주식회사 엘마이토테라퓨틱스 나프토퀴논 화합물을 포함하는 암 치료용 약학적 조성물
KR102591933B1 (ko) * 2020-02-14 2023-10-23 사회복지법인 삼성생명공익재단 게니핀 및 엘레스클로몰을 포함하는 암 예방 또는 치료용 약학적 조성물
TWI832069B (zh) * 2020-07-10 2024-02-11 南韓商娜迪安生物公司 用於預防或治療癌症且含有萘醌系化合物及免疫檢查點抑制劑作為活性成分的藥學組成物
CN111965354A (zh) * 2020-07-27 2020-11-20 温州医科大学 Ho-1蛋白在乳腺癌预后评估试剂盒、诊断试剂盒中的应用
CN112516310B (zh) * 2020-12-11 2022-11-29 武汉理工大学 一种肿瘤酸环境响应的纳米前药的制备方法及其应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9805866D0 (en) * 1998-03-20 1998-05-13 Zeneca Ltd Anti-tumour agents
US8637490B2 (en) * 2011-07-01 2014-01-28 Uwm Research Foundation, Inc. Anti-cancer agents
PL2768308T3 (pl) * 2011-10-14 2018-12-31 The Board Of Trustees Of The University Of Illinois Związki i substraty przeciwnowotworowe nqo1
US20150017673A1 (en) * 2012-08-30 2015-01-15 James Sacchettini Compositions and methods for drug-sensitization or inhibition of a cancer cell
EP2984184B1 (en) * 2013-04-09 2020-11-25 The Board of Trustees of the University of Illionis Use of dnq or dnq-87 in combination with a parp1 inhibitor for the treatment of cancer

Also Published As

Publication number Publication date
JP2019518795A (ja) 2019-07-04
EP3558317A4 (en) 2020-03-18
US20200179417A1 (en) 2020-06-11
KR20190025646A (ko) 2019-03-11
CA3029228A1 (en) 2018-01-04
WO2018005279A1 (en) 2018-01-04
EA201892834A1 (ru) 2019-07-31
EP3558317A1 (en) 2019-10-30
ZA201808608B (en) 2019-06-26
CN109689060A (zh) 2019-04-26
AU2017291411A1 (en) 2019-01-03
IL263785A (en) 2019-01-31
BR112018076639A2 (pt) 2019-04-02

Similar Documents

Publication Publication Date Title
MX2018016332A (es) Quimioterapias de combinacion.
CO2019008487A2 (es) Compuesto de quinazolina
MX379297B (es) Compuestos alqueno tetrasustituidos y su uso.
BR112017017448A2 (pt) métodos e composições para o tratamento de doença do olho ressecado e outros distúrbios do olho
ECSP17077930A (es) Métodos y kits para tratar la depresión
MX2016007851A (es) Compuestos peptidomimeticos y conjugados anticuerpo-farmaco de estos.
CO2017001994A2 (es) Compuestos activos hacia bromodominios
BR112018003984A2 (pt) anticorpos
CR20160271A (es) Compuestos peptidométicos y sus conjugados de anticuerpo-fármaco
MX2020004837A (es) Inhibidores de la vía de adenosina para el tratamiento del cáncer.
BR112017006113A8 (pt) usos de auristatina, composições farmacêuticas, formas de dosagem para o tratamento de câncer e kits.
MX2018006674A (es) Tratamiento de cancer usando 2-desoxi-2-fluoro-l-fucosa en combinacion con un inhibidor del punto de control.
CR20170085A (es) Terapia adjuntiva con 25-hidroxi vitamina d
AR096892A1 (es) Una combinación farmacéutica para el tratamiento del melanoma
BR112017023517A2 (pt) anticorpo anti-cd20 para tratamento do câncer, composição farmacêutica, método de tratamento de um paciente que sofre de câncer e uso de um anticorpo anti-cd20
AR112102A1 (es) Tinostamustina para utilizar en el tratamiento de cáncer de ovario
MX2016015437A (es) Combinacion que comprende un glucocorticoide y edo-s101.
MX392470B (es) Composición farmacéutica que comprende un péptido wt1 para el tratamiento o prevención de una enfermedad angiogénica.
MX2022014792A (es) Cocristales, composiciones farmaceuticas de los mismos y metodos de tratamiento que los implican.
CO2020001107A2 (es) Moduladores terapéuticos del modo inverso de la atp sintasa
CL2018003338A1 (es) Formulaciones inyectables fisiológicamente balanceadas de fosnetupitant.
BR112018015367A2 (pt) carreadores oromucosais de nanofibra para tratamento terapêutico
CL2021001623A1 (es) Terapia de combinación con un inhibidor de raf y un inhibidor de cdk4/6 para utilizar en el tratamiento del cáncer
CL2021000924A1 (es) Uso de reboxetina para el tratamiento de narcolepsia
CR20180080A (es) Combinaciones de un anticuerpo ox40 y un modulador de tlr4 y usos de las mismas